INHA and tuberculosis: The WHO has endorsed the commercially available molecular Line Probe Assays (LPAs), the GenoType MTBDRplus assay (Hain Lifescience, Nehren, Germany) to detect the presence of MTBC together with the most common rpoB, inhA, and katG genetic mutations that confer resistance to the most common first-line anti-TB drugs of RIF and INH [13].